Bayhill Therapeutics, Inc. and The Juvenile Diabetes Research Foundation Announce Research Collaboration for the Clinical Development of a Novel Immunotherapeutic DNA Vaccine for Type 1 Diabetes

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Bayhill Therapeutics, Inc., a leading developer of therapies for autoimmune diseases, and the Juvenile Diabetes Research Foundation, the world's leading charitable funder of type 1 diabetes research, today announced a partnership to support Bayhill’s ongoing Phase I/II human clinical trial of BHT-3021, a DNA vaccine to reverse the immune response that causes type 1 diabetes.